Home
/
Liver Function

What Level of AST Is Dangerous? Safe vs Risk Levels

REVIEWED BY
Bill Maish, MD
Clinical Content Consultant
Published
May 31, 2026
Last updated
May 30, 2026
Quick answer:

AST becomes dangerous at progressively higher thresholds: levels above 400 U/L (roughly 10 times the normal upper limit) may indicate significant tissue damage, while readings over 1,000 U/L typically signal acute hepatitis, drug toxicity, or severe muscle breakdown requiring emergency care. Normal AST ranges from 10–40 U/L in men and 9–32 U/L in women.

Read more →
Table of contents

Key Takeaways

What AST Actually Measures

AST (aspartate aminotransferase) is an enzyme that helps convert amino acids in your cells. Your liver contains the highest concentrations, followed by your heart, skeletal muscles, kidneys, and brain. When any of these tissues are damaged or stressed, they release AST into your bloodstream.

Think of AST like a smoke alarm. Just as smoke doesn't tell you whether it's from burnt toast or a house fire, elevated AST doesn't specify the exact problem. It signals that somewhere in your body, cells are breaking down and releasing their contents.

This is why doctors rarely interpret AST in isolation. They look at patterns with other liver enzymes like ALT (alanine aminotransferase), which is more liver-specific, plus symptoms and medical history. AST elevation with normal ALT often suggests muscle damage, while both elevated together typically points to liver issues.

Normal Versus Optimal AST Levels

Most laboratories define normal AST as 10-40 U/L for men and 9-32 U/L for women, though ranges vary slightly between labs. However, "normal" doesn't necessarily mean "optimal" for long-term health.

Some research suggests that standard laboratory cutoffs for aminotransferases may be set higher than ideal, since they were derived from populations that likely included subclinical liver disease. Levels in the upper end of the "normal" range may still reflect early metabolic or hepatic stress in some people. Many functional medicine practitioners prefer seeing AST below 25 U/L as a marker of robust liver health.

Your individual baseline matters more than population averages. If your AST typically runs around 15 U/L and suddenly jumps to 35 U/L, that doubling deserves attention even though 35 U/L falls within the "normal" range. This is why tracking trends over time reveals patterns that single tests might miss.

What High AST Levels Can Mean

AST elevation falls into several risk categories based on how dramatically levels exceed normal ranges. Each category may suggest different underlying causes and urgency levels.

Mild elevation (40-80 U/L) often may reflect fatty liver disease, medication effects, or recent intense exercise. This level rarely causes symptoms but warrants lifestyle evaluation and follow-up testing in 4-6 weeks.

Moderate elevation (80-400 U/L) may suggest more significant liver inflammation, chronic hepatitis, or muscle injury. You might notice fatigue, abdominal discomfort, or muscle aches. This range requires medical evaluation within days to weeks.

Severe elevation (400-1,000 U/L) may indicate acute tissue damage from drug toxicity, viral hepatitis, or severe muscle breakdown (rhabdomyolysis). This level often comes with noticeable symptoms and needs prompt medical attention.

Extreme elevation (>1,000 U/L) may signal acute hepatitis, acetaminophen overdose, or massive muscle damage. This range typically requires immediate emergency care, as it can indicate life-threatening conditions.

What Low AST Levels Can Mean

Low AST levels (below 10 U/L) are less common and generally less concerning than high levels. However, persistently low AST can provide useful health information.

Vitamin B6 deficiency is the most common cause of low AST, since pyridoxal-5-phosphate is a required cofactor for the AST assay. Other B-vitamin deficiencies, particularly folate and B12, can also influence measured aminotransferase activity.

Advanced liver disease can sometimes present with AST levels that do not rise — or even drift low — once hepatocyte mass is substantially reduced. Low or normal transaminases in older adults have also been associated with worse survival, and should always be interpreted alongside other markers of liver function rather than in isolation.

Pregnancy does not significantly change AST levels in the second and third trimesters compared with non-pregnant women. Normal pregnancy-related variation doesn't indicate problems unless accompanied by other liver function out-of-range values.

How AST Is Tested

AST testing requires a simple blood draw from a vein in your arm. No fasting is required specifically for AST, though if you're getting a comprehensive metabolic panel simultaneously, your doctor might request fasting for other markers like glucose.

Timing matters for accurate AST interpretation. Intense exercise within 24-48 hours before testing can elevate AST due to muscle breakdown. Recent alcohol consumption, even moderate amounts, can temporarily raise levels. Certain medications, including statins, acetaminophen, and herbal supplements, can also influence results.

Retest timing depends on your initial levels and suspected causes. Mild elevations typically warrant retesting in 4-6 weeks after addressing potential causes. Moderate to severe elevations might need weekly monitoring until levels normalize. Once stable, annual monitoring suffices for most people.

Sample handling affects results, so ensure your blood is processed within a few hours of collection. Hemolysis (red blood cell breakdown during collection) can artificially elevate AST, requiring sample recollection.

What Can Change AST

Exercise intensity significantly impacts AST levels. Marathon running or intense weightlifting can double or triple AST for 24-72 hours post-exercise. Regular moderate exercise may reduce liver fat, which can support healthier long-term aminotransferase patterns.

Alcohol consumption raises AST within hours and can keep levels elevated for days. Even moderate drinking (2-3 drinks) can temporarily increase AST in sensitive individuals. Chronic alcohol use creates persistently elevated levels that can take weeks to normalize after stopping.

Medications frequently affect AST levels. Statins, acetaminophen, antibiotics, and many herbal supplements can cause elevation. Always inform your doctor about all medications and supplements when interpreting AST results.

Weight changes influence AST through their effects on liver fat accumulation. Weight loss of 5-10% often significantly improves AST levels in people with fatty liver disease. Conversely, rapid weight gain can raise liver-related enzymes.

Connecting AST to Related Biomarkers

ALT (alanine aminotransferase) provides crucial context for AST interpretation. When AST exceeds ALT by more than 2:1, suspect alcohol-related liver damage or advanced liver disease. When ALT exceeds AST, think viral hepatitis or medication-induced liver injury.

Bilirubin and alkaline phosphatase help distinguish between hepatocellular damage (affecting liver cells directly) and cholestatic problems (affecting bile flow). Elevated AST with normal bilirubin and alkaline phosphatase may suggest early or mild liver cell damage.

Creatine kinase (CK) differentiates muscle from liver sources when AST is elevated. High AST with elevated CK points to muscle breakdown, while high AST with normal CK suggests liver issues.

GGT (gamma-glutamyl transferase) adds another layer of liver-specific information. Elevated AST with elevated GGT strongly suggests liver involvement, while isolated AST elevation with normal GGT might indicate muscle sources.

Why Testing AST Is Worth It

AST provides an early warning system for liver and muscle health that symptoms alone can't match. Many liver conditions remain asymptomatic until significant damage occurs, making regular AST monitoring valuable for prevention rather than just diagnosis.

Trend tracking reveals patterns invisible in single tests. Gradually rising AST over months might indicate developing fatty liver disease, while sudden spikes suggest acute problems requiring immediate attention. This longitudinal view helps distinguish concerning changes from temporary fluctuations.

Risk stratification improves when AST is combined with other biomarkers. People whose AST, lipid profile, and inflammatory markers all sit within healthy ranges generally have a more favorable composite cardiometabolic picture than those with isolated abnormalities.

Treatment monitoring relies heavily on AST trends. Whether you're addressing fatty liver through lifestyle changes or managing hepatitis with medication, AST levels provide objective feedback about intervention effectiveness long before symptoms improve or resolve.

Take Control of Your AST Levels

Understanding what level of AST is dangerous gives you the framework to interpret your results, but tracking these levels over time reveals the complete story of your liver and muscle health. Single elevated readings might reflect temporary stress, while persistent elevation or concerning trends demand action.

Superpower's Superpower biomarker panel includes AST alongside ALT, bilirubin, and other liver function markers, giving you the complete hepatic health picture rather than isolated numbers. Our Advanced biomarker panel adds inflammatory markers and advanced lipid testing that help interpret AST changes in full context.

Get your AST tested with Superpower's comprehensive biomarker panel and start tracking the trends that matter for your long-term liver health.

FAQs

AST levels above 400 U/L (10 times the upper limit) are considered alarming and suggest significant tissue damage. Levels above 1,000 U/L typically indicate acute hepatitis, drug toxicity, or severe muscle breakdown requiring immediate medical attention.

Yes, the liver can recover from high AST levels once the underlying cause is addressed. AST levels often normalize within days to weeks after removing the damaging factor, such as stopping problematic medications or treating viral hepatitis, assuming permanent liver damage hasn't occurred.

To reduce AST levels, address the underlying cause: avoid alcohol, maintain a healthy weight, exercise regularly but avoid intense workouts before testing, review medications with your doctor, and treat any underlying liver conditions. Weight loss of 5-10% can significantly improve AST in people with fatty liver disease.

Mildly elevated AST often causes no symptoms. Moderate to severe elevation may cause fatigue, abdominal discomfort, nausea, or muscle aches. Very high AST (>1,000 U/L) typically comes with noticeable symptoms like severe fatigue, abdominal pain, or jaundice, depending on the underlying cause.

AST is found in liver, muscles, heart, and other tissues, while ALT is more liver-specific. When AST is elevated without ALT elevation, it often suggests muscle damage. When both are elevated, it typically indicates liver problems. The AST/ALT ratio helps doctors determine the likely source of elevation.

Extreme AST elevation above 1,000 U/L typically signals acute hepatitis, acetaminophen overdose, or massive muscle damage and often requires immediate emergency care. Severe elevation in the 400-1,000 U/L range with noticeable symptoms like jaundice or severe abdominal pain also warrants prompt — often same-day — medical evaluation.

References

  1. Kwo, P. Y., Cohen, S. M., & Lim, J. K. (2017). ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. The American journal of gastroenterology, 112(1), 18-35. https://doi.org/10.1038/ajg.2016.517
  2. Larson, A. M., Polson, J., Fontana, R. J., Davern, T. J., Lalani, E., Hynan, L. S., Reisch, J. S., Schiødt, F. V., Ostapowicz, G., Shakil, A. O., Lee, W. M., & Acute Liver Failure Study Group (2005). Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology (Baltimore, Md.), 42(6), 1364-72. https://doi.org/10.1002/hep.20948
  3. Pettersson, J., Hindorf, U., Persson, P., Bengtsson, T., Malmqvist, U., Werkström, V., & Ekelund, M. (2008). Muscular exercise can cause highly pathological liver function tests in healthy men. British journal of clinical pharmacology, 65(2), 253-9. https://doi.org/10.1111/j.1365-2125.2007.03001.x
  4. https://pubmed.ncbi.nlm.nih.gov/29494096/
  5. Giannini, E. G., Testa, R., & Savarino, V. (2005). Liver enzyme alteration: a guide for clinicians. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 172(3), 367-79. https://doi.org/10.1503/cmaj.1040752
  6. Prati, D., Taioli, E., Zanella, A., Della Torre, E., Butelli, S., Del Vecchio, E., Vianello, L., Zanuso, F., Mozzi, F., Milani, S., Conte, D., Colombo, M., & Sirchia, G. (2002). Updated definitions of healthy ranges for serum alanine aminotransferase levels. Annals of internal medicine, 137(1), 1-10. https://doi.org/10.7326/0003-4819-137-1-200207020-00006
  7. Stravitz, R. T., & Lee, W. M. (2019). Acute liver failure. Lancet (London, England), 394(10201), 869-881. https://doi.org/10.1016/S0140-6736(19)31894-X
  8. Bosch, X., Poch, E., & Grau, J. M. (2009). Rhabdomyolysis and acute kidney injury. The New England journal of medicine, 361(1), 62-72. https://doi.org/10.1056/NEJMra0801327
  9. Clayton-Chubb, D., Majeed, A., Roberts, S. K., Schneider, H. G., Commins, I., Fitzpatrick, J., Woods, R. L., Ryan, J., Hussain, S. M., Tan, N., Lubel, J. S., Tran, C., Hodge, A. D., McNeil, J. J., & Kemp, W. W. (2024). Serum Transaminases and Older Adults: Distribution and Associations With All-Cause Mortality. The journals of gerontology. Series A, Biological sciences and medical sciences, 79(11). https://doi.org/10.1093/gerona/glae203
  10. Tarrant, J., Meyer, D., & Katavolos, P. (2013). Use of optimized aminotransferase methods in regulated preclinical studies. Veterinary clinical pathology, 42(4), 535-8. https://doi.org/10.1111/vcp.12082
  11. Bacq, Y., Zarka, O., Bréchot, J. F., Mariotte, N., Vol, S., Tichet, J., & Weill, J. (1996). Liver function tests in normal pregnancy: a prospective study of 103 pregnant women and 103 matched controls. Hepatology (Baltimore, Md.), 23(5), 1030-4. https://doi.org/10.1002/hep.510230514
  12. Conigrave, K. M., Davies, P., Haber, P., & Whitfield, J. B. (2003). Traditional markers of excessive alcohol use. Addiction (Abingdon, England), 98 Suppl 2, 31-43. https://doi.org/10.1046/j.1359-6357.2003.00581.x
  13. Chalasani, N. P., Maddur, H., Russo, M. W., Wong, R. J., Reddy, K. R., & Practice Parameters Committee of the American College of Gastroenterology (2021). ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury. The American journal of gastroenterology, 116(5), 878-898. https://doi.org/10.14309/ajg.0000000000001259
  14. Boyanton, B. L., & Blick, K. E. (2002). Stability studies of twenty-four analytes in human plasma and serum. Clinical chemistry, 48(12), 2242-7. https://pubmed.ncbi.nlm.nih.gov/12446483/
  15. Lippi, G., Salvagno, G. L., Montagnana, M., Brocco, G., & Guidi, G. C. (2006). Influence of hemolysis on routine clinical chemistry testing. Clinical chemistry and laboratory medicine, 44(3), 311-6. https://doi.org/10.1515/CCLM.2006.054
  16. Keating, S. E., Hackett, D. A., George, J., & Johnson, N. A. (2012). Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. Journal of hepatology, 57(1), 157-66. https://doi.org/10.1016/j.jhep.2012.02.023
  17. Nyblom, H., Berggren, U., Balldin, J., & Olsson, R. (2004). High AST/ALT ratio may indicate advanced alcoholic liver disease rather than heavy drinking. Alcohol and alcoholism (Oxford, Oxfordshire), 39(4), 336-9. https://doi.org/10.1093/alcalc/agh074
  18. Chalasani, N., Aljadhey, H., Kesterson, J., Murray, M. D., & Hall, S. D. (2004). Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology, 126(5), 1287-92. https://doi.org/10.1053/j.gastro.2004.02.015
  19. Singer, A. J., Carracio, T. R., & Mofenson, H. C. (1995). The temporal profile of increased transaminase levels in patients with acetaminophen-induced liver dysfunction. Annals of emergency medicine, 26(1), 49-53. https://doi.org/10.1016/s0196-0644(95)70237-7
  20. Promrat, K., Kleiner, D. E., Niemeier, H. M., Jackvony, E., Kearns, M., Wands, J. R., Fava, J. L., & Wing, R. R. (2010). Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology (Baltimore, Md.), 51(1), 121-9. https://doi.org/10.1002/hep.23276
  21. Kechagias, S., Ernersson, A., Dahlqvist, O., Lundberg, P., Lindström, T., Nystrom, F. H., & Fast Food Study Group (2008). Fast-food-based hyper-alimentation can induce rapid and profound elevation of serum alanine aminotransferase in healthy subjects. Gut, 57(5), 649-54. https://doi.org/10.1136/gut.2007.131797
  22. Sorbi, D., Boynton, J., & Lindor, K. D. (1999). The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. The American journal of gastroenterology, 94(4), 1018-22. https://doi.org/10.1111/j.1572-0241.1999.01006.x
  23. Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016). Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology (Baltimore, Md.), 64(1), 73-84. https://doi.org/10.1002/hep.28431

Built by the world’s top doctors and scientists

Dr Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Board-certified longevity physician. Previously product leader at Virta Health & CMO at Modern Age. Featured in  WSJ, Forbes, and Fortune.

Learn more

Dr Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Leads the largest integrative medical clinic in North America. A pioneer in integrative oncology.

Learn more

Dr Robert Lufkin

UCLA Medical Professor, NYT Bestselling Author

A leading voice on metabolic health and longevity as shown in The Today Show, USA Today and FOX.

Learn more

Dr Abe Malkin

Founder & Medical Director of Concierge MD

Leads a nationwide medical practice, and Drip Hydration, a mobile IV therapeutics company

Learn more
Membership slide 1
Membership slide 1
Membership slide 2
Membership slide 3
1 / 3

Your membership starts here

Annual 100+ biomarker panel

Data dashboard and digital twin

Upload past labs and connect wearables

Personalized health protocol

24/7 care team access

AI companion for all health questions

Marketplace with additional solutions

$199

/year*

Billed annually

HSA/ FSA eligible
Cancel anytime
Results in a week

* Pricing may vary for members in New York and New Jersey